Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
March 2003
Features
Drug Safety Revisions: FDA Update
The author reviews the reasons for FDA labeling changes for estrogens and estrogen–progesterone combinations as hormonal therapy; sertraline for depression; and palivizumab as prophylactic therapy for respiratory infections.
Marvin M. Goldenberg, PhD, RPh, MS
Chronic Pain Management in Managed Care Organizations: A National Survey of Medical Directors
The authors present the results of a survey sent to the directors of MCOs to ascertain their views on chronic pain in their patients.
Chureen Carter, PharmD, Neil I. Goldfarb, Christine W. Hartmann, MSS, Adam R. Roumm, Susan M. Vallow, MBA, MA, and Michael Durkin, MS
Ezetimibe: The First Cholesterol Absorption Inhibitor
The first of the new selective cholesterol absorption inhibitors, ezetimibe has been approved for several indications.
Beata M. Domagala, PharmD, Michelle Leady, PharmD, and Daniel S. Streetman, PharmD
Cover Story
Looking Ahead: Recommendations for Planning and Improving Adult Vaccination Programs
Now is the time to order vaccine for the fall flu season. The authors discuss the ways in which many diseases in older adults could be prevented with more effective immunization strategies.
S. Jay Weaver, PharmD, and Paul L. Doering, MS Pharm
Departments
Editorial
“Transparent” Power: The New Milliman Guidelines
David B. Nash, MD, MBA
Spotlight
Editor’s Memo: Online at Last!
P&T is now accessible on the World Wide Web. But wait, there’s more!
Sonja Sherritze
Medication Errors
“Magic Words” or “Red Flags?”
Matthew Grissinger discusses some key words that should be considered “red flags.”
Matthew Grissinger
Drug News
New Drugs/Drug News
The latest information about approvals, indication changes, industry updates, and news from the FDA.
P&T Snapshot
Select SSRIs Increase Level of HMO Drug Formulary Access Despite Generic Incursion
Prescription Washington
Incremental Progress Improving Medication Administration
Stephen Barlas ponders the tragic loss of life caused by a medical error.
Stephen Barlas
Drug Forecast
Interferon beta-1a in the Treatment of Multiple Sclerosis
Dr. Liang-Kim reviews the role of interferon beta-1a in multiple sclerosis.
Kathleen S. Liang-Kim, RPh
P&T Snapshot
Medical Errors: Facing the Numbers
